Tofogliflozin (hydrate)

SKU: orb1302166

Description

Tofogliflozin (hydrate)

Research Area

Immunology & Inflammation, Metabolism Research, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 1201913-82-7
• MW: 404.45
• Purity: 97.03%
• Formula: C₂₂H₂₈O₇
• SMILES: O.CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1
• Target: SGLT,Reactive Oxygen Species,ROS
• Solubility: DMSO:90 mg/mL (222.52 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (8.16 mM);H2O:0.33 mg/mL (0.82 mM)

Bioactivity

• Target IC50:
  SGLT2:6.4 nM(Ki)|SGLT2 (rat):14.9 nM(Ki) |SGLT2:2.9 nM |SGLT2 (human):2.9 nM(Ki)
• In Vitro:
  Tofogliflozin, a highly selective inhibitor of SGLT2 on oxidative stress generation, inflammatory and proapoptotic reactions in cultured human proximal tubular cells exposed to high glucose. Tofogliflozin dose-dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were suppressed by the treatment of tofogliflozin or an antioxidant N-acetylcysteine (NAC). Monocyte chemoattractant protein-1 (MCP-1) gene expression and apoptotic cell death were induced by 4 h- and 8 day-exposure to high glucose, respectively, both of which were also blocked by tofogliflozin or NAC. The present study suggests that SGLT2-mediated glucose entry into tubular cells could stimulate oxidative stress and evoke inflammatory and proapoptotic reactions in this cell type. Blockade of glucose reabsorption in tubular cells by SGLT2 inhibitor might exert beneficial effects on tubulointerstitial damage in diabetic nephropathy.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CSG 452, CSG 452 Hydrate, CSG452, CSG-452, CSG452 Hydrate, CSG-452 Hydrate, CSG-452 hydrate, Inhibitor, inhibit, Sodium-dependent glucose cotransporters, Tofogliflozin, Tofogliflozin (hydrate), Tofogliflozin Hydrate, Tofogliflozin hydrate, ROS, Reactive Oxygen Species, ReactiveOxygenSpecies, SGLT2, SGLT

Compound Identifiers

PubChem CID

46908928